GnRH-Antagonisten in der kontrollierten ovariellen Stimulation
暂无分享,去创建一个
[1] G. Haidl,et al. Andrology and clinical sciences. , 1998, Human reproduction.
[2] K. Diedrich,et al. Komplikationen der assistierten Reproduktion , 1996, Der Gynäkologe.
[3] K. Diedrich,et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages , 1996, Journal of Assisted Reproduction and Genetics.
[4] A. Balen. The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. , 1995, Human reproduction.
[5] A. Schally,et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. , 1995, Human reproduction.
[6] D. Klingmüller,et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. , 1994, Human reproduction.
[7] B. Tarlatzis,et al. The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. , 1992, Human reproduction.
[8] K. Thomas,et al. Short‐term Utilization of a Gonadotropin‐Releasing Hormone Agonist (Buserelin) for Induction of Ovulation in an in Vitro Fertilization Program , 1988, Annals of the New York Academy of Sciences.
[9] J. Yovich,et al. Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase , 1985, British journal of obstetrics and gynaecology.
[10] K. Diedrich,et al. Three years of routine vitrification of human zygotes: is it still fair to advocate slow-rate freezing? , 2007, Reproductive biomedicine online.